Plasma Glycated CD59 Predicts Early Gestational Diabetes and Large for Gestational Age Newborns.
Adult
Biomarkers
/ blood
Blood Glucose
/ analysis
CD59 Antigens
/ blood
Diabetes, Gestational
/ blood
Female
Fetal Macrosomia
/ blood
Follow-Up Studies
Gestational Age
Glycosylation
Humans
Infant, Newborn
Infant, Newborn, Diseases
/ blood
Pregnancy
Pregnancy Complications
/ blood
Prognosis
Risk Factors
Young Adult
biomarkers
epidemiology
gestational diabetes mellitus
glycation
prediction
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
24
10
2019
accepted:
15
02
2020
pubmed:
19
2
2020
medline:
5
1
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Gestational diabetes mellitus (GDM) diagnosed in early pregnancy is a health care challenge because it increases the risk of adverse outcomes. Plasma-glycated CD59 (pGCD59) is an emerging biomarker for diabetes and GDM. The aim of this study was to assess the performance of pGCD59 as a biomarker of early GDM and its association with delivering a large for gestational age (LGA) infant. To assess the performance of pGCD59 to identify women with GDM in early pregnancy (GDM < 20) and assess the association of pGCD59 with LGA and potentially others adverse neonatal outcomes linked to GDM. Blood levels of pGCD59 were measured in samples from 693 obese women (body mass index > 29) undergoing a 75-g, 2-hour oral glucose tolerance test (OGTT) at <20 weeks' gestation in the Vitamin D and Lifestyle Intervention study: the main analyses included 486 subjects who had normal glucose tolerance throughout the pregnancy, 207 who met criteria for GDM at <20 weeks, and 77 diagnosed with GDM at pregnancy weeks 24 through 28. Reference tests were 75-g, 2-hour OGTT adjudicated based on International Association of Diabetes and Pregnancy Study Group criteria. The index test was a pGCD59 ELISA. Mean pGCD59 levels were significantly higher (P < 0.001) in women with GDM < 20 (3.9 ± 1.1 standard peptide units [SPU]) than in those without (2.7 ± 0.7 SPU). pGCD59 accurately identified GDM in early pregnancy with an area under the curve receiver operating characteristic curves of 0.86 (95% confidence interval [CI], 0.83-0.90). One-unit increase in maternal pGCD59 level was associated with 36% increased odds of delivering an LGA infant (odds ratio for LGA vs non-LGA infant: 1.4; 95% CI, 1.1-1.8; P = 0.016). Our results indicate that pGCD59 is a simple and accurate biomarker for detection of GDM in early pregnancy and risk assessment of LGA.
Identifiants
pubmed: 32069353
pii: 5740160
doi: 10.1210/clinem/dgaa087
pmc: PMC7082084
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
CD59 Antigens
0
CD59 protein, human
101754-01-2
Banques de données
ISRCTN
['ISRCTN70595832']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK101442
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118528
Pays : United States
Investigateurs
David Simmons
(D)
Rosa Corcoy
(R)
Roland Devlieger
(R)
Dirk Timmerman
(D)
Alexandra Kautzky-Willer
(A)
Andre van Assche
(A)
Peter Damm
(P)
Elisabeth Mathiesen
(E)
Dorte Møller Jensen
(D)
Lise Lotte Andersen
(L)
Annunziata Lapolla
(A)
Alessandra Bertolotto
(A)
Maria Grazia Dalfrá
(MG)
Frank Snoek
(F)
Mireille van Poppel
(M)
Ewa Wender-Ożegowska
(E)
Agnieszka Zawiejska
(A)
David Hill
(D)
Informations de copyright
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Eur J Obstet Gynecol Reprod Biol. 1991 Feb 25;38(3):217-20
pubmed: 2007448
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 32069353
Am J Hematol. 2017 Nov;92(11):1198-1203
pubmed: 28815695
Diabetes Care. 2019 Mar;42(3):372-380
pubmed: 30655380
Am J Obstet Gynecol. 1991 Oct;165(4 Pt 1):914-9
pubmed: 1951553
J Clin Endocrinol Metab. 2017 Mar 01;102(3):903-913
pubmed: 27935767
Obstet Gynecol. 2018 Aug;132(2):496-505
pubmed: 29995731
Acta Obstet Gynecol Scand. 2005 Dec;84(12):1159-63
pubmed: 16305701
N Engl J Med. 2005 Jun 16;352(24):2477-86
pubmed: 15951574
N Engl J Med. 2009 Oct 1;361(14):1339-48
pubmed: 19797280
Diabetes Care. 2019 Mar;42(3):381-392
pubmed: 30617141
Ann Intern Med. 2014 Mar 18;160(6):414-20
pubmed: 24424622
N Engl J Med. 2008 May 8;358(19):1991-2002
pubmed: 18463375
BMC Pregnancy Childbirth. 2013 Jul 05;13:142
pubmed: 23829946
Immunol Res. 1993;12(3):258-75
pubmed: 7507156
Diabetes Care. 2016 Jan;39(1):75-81
pubmed: 26645084
Diabetes Res Clin Pract. 2014 Mar;103(3):341-63
pubmed: 24847517
Am J Hematol. 2013 Aug;88(8):670-6
pubmed: 23670858
Acta Obstet Gynecol Scand. 2005 Jul;84(7):622-7
pubmed: 15954869
Obstet Gynecol. 2018 Feb;131(2):406-408
pubmed: 29370044
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
J Clin Endocrinol Metab. 2014 Jun;99(6):E999-E1006
pubmed: 24628556
Diabetes Care. 2007 Sep;30(9):2287-92
pubmed: 17519427
Diabetes Care. 1990 Aug;13(8):872-5
pubmed: 2209322
Am J Obstet Gynecol. 1993 Oct;169(4):874-81
pubmed: 8238142
Diabetes Care. 2017 Jul;40(7):981-984
pubmed: 28450368
Diabetes Res Clin Pract. 2004 Jan;63(1):73-4
pubmed: 14693415
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5450-5
pubmed: 10805801
Diabetologia. 2018 May;61(5):1012-1021
pubmed: 29356835
Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):41-4
pubmed: 12818441
Nat Rev Dis Primers. 2019 Jul 11;5(1):47
pubmed: 31296866
Stat Med. 1997 May 15;16(9):965-80
pubmed: 9160492
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132